Medytox, Inc. v. ITC — Fed. Cir. (Nov 9, 2026)

No. 25-1262 Argued November 9, 2026 Published November 10, 2026

The Federal Circuit hears Medytox's appeal in a dispute over the bacteria used to make botulinum toxin products. Medytox accused a rival manufacturer, Hugel, of wrongfully taking its bacterial culture and sought action against imported products at the United States International Trade Commission. An administrative law judge rejected the claim, and the Commission agreed that Medytox had not proved that its property had been converted. The earlier trade-secret allegations had already been removed from the investigation; the issue now is the alleged wrongful taking of property. Medytox will ask the court to overturn the Commission's finding, while the Commission will defend it. As you listen, keep the burden of proof in view: questioning a rival's story is not the same as proving that it took property that belonged to you.

Medytox, Inc. v. ITC (No. 25-1262) — U.S. Court of Appeals for the Federal Circuit, argued November 9, 2026.

Sources

Argument audio — official Federal Circuit recording, November 9, 2026; complete source with gentle volume balancing, no noise filtering or speech reconstruction:https://www.cafc.uscourts.gov/oral-arguments/25-1262_11092026.mp3

Commission notice — U.S. International Trade Commission, Investigation No. 337-TA-1313, October 10, 2024:https://www.usitc.gov/system/files/secretary/fed_reg_notices/337/337_1313_notice10102024sgl.pdf

Medytox investigation-institution statement — attributed party account, May 3, 2022:https://www.medytox.com/en/media/news/881

Hugel initial-determination statement — party account, June 10, 2024:https://www.hugel-inc.com/pr-en/rec7VC2i0wScSruon

0:00Introduction